HOME >> MEDICINE >> NEWS
Chemotherapy may enhance the effectiveness of brain tumor vaccines

ding means that instead of having to receive the two therapies separately, patients might benefit from the delivery of a one-two punch to brain tumors, Sampson said.

Average survival for patients with newly diagnosed, surgically treated glioblastoma multiforme is 15 months with standard therapy, including chemotherapy. Patients who receive vaccine treatments with chemotherapy have exceeded expectations.

"Vaccines are an extremely promising new therapy for brain tumors, and the fact that their effectiveness may be augmented by chemotherapy represents the potential for an exciting new trend in brain tumor treatment," Sampson said.


'"/>

Contact: Lauren Shaftel
lauren.shaftel@duke.edu
919-452-2037
Duke University Medical Center
3-Jun-2007


Page: 1 2

Related medicine news :

1. Chemotherapy with bevacizumab increases risk of blood clots in arteries
2. Chemotherapy more effective when given before breast cancer surgery
3. Chemotherapy temporarily affects the structures of the human brain
4. Chemotherapy gel may fight breast cancer and reduce breast deformity
5. Chemotherapy given directly to the liver improves survival for patients with colorectal cancer
6. Chemotherapy after surgery extends survival for patients with advanced endometrial cancer
7. Chemotherapy errors rare, but have potential for serious consequences
8. Chemotherapy for brain tumors is boosted after vaccine targets resistance-related antigen
9. Chemotherapy options improve for patients with advanced colorectal cancer
10. Emergency department guidelines enhance quality patient care
11. Using nanomagnets to enhance medical imaging

Post Your Comments:
(Date:6/19/2013)... 2013 Maui'd Forever , Hawaii's ... being an effective and cost effective way to provide ... partnered up with Tom Barefoot’s Tours providing an activity ... of Hawaii’s activities. , They have just released a ... the lowest prices on their Hawaii activities. , ...
(Date:6/19/2013)... June 19, 2013 According to Transparency ... Market Share, Trends, Analysis and Forecast, 2011 – 2017,” ... billion in the year 2011 and is expected to ... CAGR of 9.7% from 2011 to 2017. Flexible endoscopes ... contributing about USD 2,201 million for the year 2011. ...
(Date:6/19/2013)... neurologists treating stroke victims has been "time equals brain." That,s ... receive a drug that dissolves the stroke-causing blood clot can ... saved or lost. , But specific information has ... intravenous drug known as a tissue plasminogen activator, or ... the most common type of stroke. , Now, ...
(Date:6/19/2013)... Il. A Loyola University Chicago Niehoff School of ... to study whether Vitamin D can improve mood in ... also will examine whether vitamin D supplementation can reduce ... diabetes. The grant is from the National Institute of ... Principal investigator Sue M. Penckofer, PhD, RN and colleagues ...
(Date:6/19/2013)... June 19, 2013 AquaPrint Solutions in Thomson, ... & Grub with a newly-designed Harley Davidson motorcycle gas tank. ... AquaPrint Solutions with an idea of taking a split tank ... ages and transforming it into a work of art. ... & Grub several toilet seats that had been dipped in ...
Breaking Medicine News(10 mins):Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2
(Date:6/19/2013)... 19, 2013  Finesse Solutions, Inc, a manufacturer ... process applications, announced the launch of its new ... culture and fermentation.  The 3L glass vessels are ... Finesse bioreactors and are designed to optimize yield ... fully compatible with all Finesse G3Lab controllers, and ...
(Date:6/19/2013)...  Decision Resources, one of the world,s leading ... issues, finds that, for the treatment of rheumatoid ... rheumatologists cite a therapy,s induction of remission as ... prescribing decisions. Over 60 percent and 70 percent ... percentage of patients achieving remission at six months ...
(Date:6/19/2013)... , June 19, 2013   Nektar Therapeutics ... from a human abuse liability (HAL) study for NKTR-181, ... of entry into the brain.  This slow rate of entry ... the abuse of and addiction to current opioid analgesics. 1 ... was rated similar to placebo in "drug liking" and ...
Breaking Medicine Technology:Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
Cached News: